A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarthritis,and traumatic brain injury. The company also provides Patient Pure X, an autologous biologic, that helps reduce inflammation and promote tissue healing and regeneration. In addition, it develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROWX, ZEO HAIR GROW, and ZEO GROW BOOST, a serum comprised of hair growth stimulants for follicle stimulation. The company has a strategic collaboration with Regen Therapy Limited for the development of biologic therapeutics. The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is based in Davie, Florida.
Financial Summary
| Share Statistics | ZEOX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.0 | $272.7 | 6% |
|
| Shares Out (Mil) | 7.8 | 54.1 | 18% |
|
| Institutional Ownership | na | 93.0% | na |
|
| Float (Mil) | na | 42.3 | na |
|
| Beta | 1.65 | 0.95 | 86% |
|
| Avg Daily Volume (000s) | 2 | 471 | 9% |
|
| Price Change (52-week) |
(33.9%) | 56.7% | 24% |
|
| Growth | ZEOX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.9% | 14.1% | 62% |
|
| Net Income (5yr) | 15.3% | (10.1%) | 64% |
|
| EPS (5yr) | 25.5% | 15.7% | 76 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.1%) | (15.6%) | 33% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ZEOX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $37 | 7% |
|
| Net Income (TTM) (Mil) | ($4) | ($43) | 34% |
|
| EPS (TTM) | ($0.561) | ($1.600) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($1) | ($31) | 30% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $11 | $185 | 8% |
|
| Valuation | ZEOX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 12.78 | 2.68 | 93% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZEOX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.5% | 67.6% | 89% |
|
| Net Margin | (55.6%) | (73.5%) | 11% |
|
| ROA | (146.0%) | (47.9%) | 3% |
|
| ROE | 559.7% | (55.0%) | 100% |
|
| Liabilities to Assets | 81.7% | 29.7% | 76% |
|
| F-Score | 4 | 3 | 33% |
|
Zeo ScientifiX, Inc. did not pass any screens on 9/10/2026.
